Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Study to Investigate the Efficacy and Safety of MS-553 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

NCT05272813 is registered in ClinicalTrials.gov with Shenzhen MingSight Relin Pharmaceuticals Co., Ltd. as lead sponsor.

NCT NCT05272813
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05272813 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Study to Investigate the Efficacy and Safety of MS-553 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Lead sponsor
Shenzhen MingSight Relin Pharmaceuticals Co., Ltd.
Phase
Phase 1/2
Overall status
Terminated
Start date
April 28, 2022
Completion date
November 28, 2023
Enrollment
13 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

lymphocytic leukemia, small lymphocytic lymphoma